Table 3 Outcomes of etomidate vs. control stratified by hydrocortisone use
From: Etomidate and mortality in cirrhotic patients with septic shock
| Â | Etomidate (n = 23) | Control (n = 39) | ||||
|---|---|---|---|---|---|---|
| Â | Hydrocortisone | Placebo | P-Value | Hydrocortisone | Placebo | P-value |
| Â | N = 14 | N = 9 | Â | N = 20 | N = 19 | Â |
ICU mortality, No.% | 12 (85.7) | 9 (100) | 0.50 | 12 (60) | 13 (68.4) | 0.74 |
Hospital mortality, No.% | 14 (100) | 9 (100) | Â | 18 (90) | 19 (100) | 0.49 |
28-day mortality, No.% | 13 (92.9) | 8 (88.9) | 1.0 | 18 (90) | 15 (79) | 0.41 |
Delta norepinephrine (d2-1) (μ/kg/min) | -0.05 ± 0.23 | 0.15 ± 0.36 | 0.05 | -0.10 ± 0.24 | 0.08 ± 0.25 | 0.02 |
Delta norepinephrine (d3-1) (μ/kg/min) | -0.10 ± 0.26 | 0.31 ± 0.36 | 0.01 | -0.20 ± 0.33 | 0.06 ± 0.28 | 0.02 |
ICU length of stay (days), mean ± SD | 13.7 ± 7.2 | 10.9 ± 8.5 | 0.23 | 9.4 ± 5.9 | 9.3 ± 5.6 | 0.93 |
Ventilation-free days, mean ± SD | 3.6 ± 5.6 | 0.2 ± 0.4 | 0.04 | 6.2 ± 6.6 | 5.8 ± 8.5 | 0.6 |
Vasopressor-free days, mean ± SD | 4.6 ± 6.9 | 1.1 ± 3.3 | 0.05 | 7.1 ± 8.0 | 3.8 ± 7.5 | 0.20 |